Three peptides modelling a highly potent, 35-residue chymotrypsin inhibitor (Schistocerca gregaria chymotrypsin inhibitor) were designed and synthesized by convergent peptide synthesis. For each model peptide, the inhibitory constant (K i ) on chymotrypsin and the solution structure were determined. In addition, molecular dynamics calculations were performed for all of them. Two models containing approximately half of the parent inhibitor (17 of 35 residues) were designed and subsequently found to have no substantial inhibitory activity (K i values in the mM range). The third model composed of 24 amino acid residues proved to be an effective (K i » 10 ±7 ) inhibitor of bovine chymotrypsin. Both the solution structure properties determined by NMR spectroscopy and the dynamic behaviour of the latter model system are comparable to the native inhibitor. In contrast, the structure and dynamics of the ®rst two related model peptides show characteristic differences. We suggest that the conformation and exibility of the modelled protease inhibitor are crucial for its biological ef®ciency. Moreover, the structural and dynamic features of the binding loop (28±33) and those of the rest of the molecule appear to be interdependent. Most importantly, these structural characteristics can be rationally modi®ed, at least partially, by peptide design. Keywords: molecular modelling and dynamics/NMR spectroscopy/peptide design/protease inhibition/structure± activity relationship
Introduction
Biological background and signi®cance Unanswered questions concerning the ®ne details of the structure±activity relationship of canonical serine protease inhibitors still remain. Canonical, standard mechanism serine protease inhibitors can be classi®ed into numerous structural families with different overall folds (Bode and Huber, 1991) . However, they share a characteristic common motif, the protease binding loop including residues designated P1 and P1¢ (Bode and Huber, 1991; Laskowski and Qasim, 2000) which form the scissile peptide bond cleaved by the target protease. The speci®city of inhibition is determined primarily by the side chain of the residue located at position P1, but neighbouring residues, especially those from P3 to P3¢ (Schechter and Berger, 1967) , also play an important role in establishing additional interactions with the enzyme (Schellenberger et al., 1991) . Canonical inhibitors bind in the active cleft of the enzyme in a substrate-like manner (Bode and Huber, 2000) . Unlike non-proteic inhibitors, these molecules possess all functional groups required for proper hydrolysis, thus the apparent paradox, namely that they act as inhibitors, remains to be explained. The key to inhibition is the extremely slow rate of hydrolysis of the P1±P1¢ peptide bond, which is undoubtedly a consequence of the three-dimensional structure and dynamics of the binding loop and its spatial neighbourhood (Laskowski and Qasim, 2000; Ravichandran et al., 2001; Cai et al., 2002) .
In this paper, we focus on the 35-residue peptide SGCI (Schistocerca gregaria chymotrypsin inhibitor), an inhibitor of the newly established`grasshopper family ' (Laskowski and Qasim, 2000) , recently named also`pacifastin family' (Simonet et al., 2002) . SGCI and its close homologue SGTI (Schistocerca gregaria trypsin inhibitor) were ®rst isolated in 1998 from desert locust (Hamdaoui et al., 1998) . SGCI is an outstanding chymotrypsin inhibitor [K i (bovine, pH 8.0, 25°C) = 6.2Q10 ±12 mol dm ±3 ], whereas SGTI is a good inhibitor for trypsin [K i (bovine, pH 8 .0, 25°C) = 2.1Q10 ±7 mol dm ±3 ] and an average inhibitor for chymotrypsin [K i (bovine, pH 8 .0, 25°C) = 2.0Q10 ±6 mol dm ±3 ] (Malik et al., 1999) . Related peptides, designated PMP-C and PMP-D2, were obtained from the migratory locust, Locusta migratoria, in the early 1990s (Boigegrain et al., 1992) . Sequence alignment (Figure 1 ) reveals that SGCI is an orthologue of PMP-C whereas SGTI is an orthologue of PMP-D2 [for a recent review on the inhibitor family, see Simonet et al. (Simonet et al., 2002) ].
The solution structure of PMP-D2 (Mer et al., 1994) , PMP-C (Mer et al., 1996a) , SGCI and SGTI (Ga Âspa Âri et al., 2002) was determined by NMR spectroscopy. The crystal structure of PMP-D2 and PMP-C complexed with chymotrypsin was solved recently (Roussel et al., 2001) . All these peptides share a common fold characterized by three antiparallel bpleated sheets and three conserved disul®de bridges. The protease binding loop is located near the C-terminus of the inhibitors in the spatial neighbourhood of conserved residues. Natural PMP-C and SGCI are fucosylated at Thr9 (Mer et al., 1996b) . This modi®cation was suggested to contribute to the structural stability of PMP-C (Mer et al., 1996a) , although the non-fucosylated form of both inhibitors retains full activity (Mer et al., 1996b) . The internal dynamics of PMP-D2 were studied by 13 C relaxation and molecular dynamics methods and the authors concluded that there are slow conformational motions in this peptide (Mer et al., 1996c) .
Structure of SGCI
The overall fold of SGCI, determined in our laboratory (Figure 2 ), corresponds to the typical structure characteristic of the grasshopper inhibitor family (Ga Âspa Âri et al., 2002) . The molecule contains three slightly twisted antiparallel b-sheets (spanning residues 9±10, 16±19 and 26±28) and three disul®de bonds (Cys4±Cys19, Cys17±Cys28 and Cys14±Cys33). Residues 5±8 form a type II b-turn. In SGCI, the P1±P1¢ amide linkage corresponds to a Leu±Lys bond (Leu30±Lys31) cleaved by chymotrypsin at a very slow rate (Figure 1 ). The binding loop containing the Leu30±Lys31 pair is¯anked by two disul®de bridges (Cys17±Cys28 and Cys14±Cys33). The loop facing the P3±P3¢ residue has the conserved sequence 14 CNTC 17 common to all SGCI homologues isolated from locust species. Asn15 is believed to contribute to the stabilization of the binding loop (Roussel et al., 2001) .
The core structure of SGCI is organized around Phe10, the only aromatic residue of the peptide. Ring protons of Phe10 give NOEs to numerous side-chain protons of sequentially distant residues such as Cys4, Thr8, Asp12, Cys17, Cys19 and Ala26. Therefore, the phenyl ring is almost completely buried in this small molecule, and thus unrecognizable by chymotrypsin.
R.m.s.d. values show that the three antiparallel b-sheets are the best de®ned parts of the structure (backbone r.m.s.d.: 0.39 T 0.11 A Ê ). As expected, the two terminal regions (residues 1±3 and 33±35) possess a limited number of NOE distance restraints, therefore these segments are represented by a family of conformers in the NMR ensemble (Ga Âspa Âri et al., 2002) . Interestingly, the protease binding loop (residues 28±33) is represented by a relatively high backbone r.m.s.d. value (0.78 T 0.23 A Ê ), indicating that this region is not as well de®ned as the core of the molecule and, possibly, exhibits a greater degree of¯exibility. This is not an uncommon ®nding among canonical inhibitors whose structure and dynamics were investigated by NMR (Shaw et al., 1995; Liu et al., 1996 Liu et al., , 1998 .
Design and synthesis of inhibitor models
Although the sequence of the P1±P1¢ (Leu30±Lys31) region in SGCI resembles a good substrate for chymotrypsin, SGCI is actually a highly potent inhibitor of chymotrypsin. The solution of this apparent contradiction lies in the three-dimensional structure of SGCI, concerning especially the conformation and dynamics of the protease binding loop (Laskowski and Qasim, 2000) .
The goal of the present study was to ®nd the`minimal' structural parts of SGCI responsible for inhibition. SGCI was chosen as a model because of its small size and compact structure. We assumed that retaining the protease binding loop with the P1±P1¢ site and the residues located in its close sequential and structural neighbourhood (as a minimum, residues 28±33 and 13±16), the inhibitory activity can be more or less retained, even on removing the`inactive parts'. In contrast to alanine scan and other`linear' sequence-trimming and residue-substitution approaches, our concept is entirely conformation-based. We found only a limited number of attempts described in the literature using conceptionally comparable approaches to investigate structure±activity relationships of protease inhibitors. Studies using interleukin 1b as a scaffold for the reactive site loop of a1 antitrypsin Arico-Muendel et al., 1999) and investigations with cyclic nonapeptides corresponding to the protease-binding part of a Bowman±Birk inhibitor (Terada et al., 1980; Dittmann et al., 2001) should be mentioned here.
To test our hypothesis, three model peptides, denoted MP1, MP2 (17 residues) and MP3 (24 residues), containing selected regions of SGCI were designed (Figure 3) [details of their synthesis were described by Mucsi et al. (Mucsi et al., 2002) ]. As these regions are not formed by a continuous polypeptide chain but rather by residues located in distant parts of the original sequence, we applied chemical modi®cations such as cyclization and isopeptide bond formation (i.e. bAsp-NH-and gGlu-NH-) to keep the conformation of the selected parts native-like. In order to retain the original b-sheet structures in the model, of reduced peptide main chain length, antiparallel bsheets b1 and b2 were closed by a¯exible Gly±Gly`bridge' to form a cyclopeptide ring of either 10 or 14 amino acid residues. The other fragment composed from 7 or 10 amino acid residues was linked to the cyclopeptide ring as a`tail-peptide'. In order to simplify the synthesis, selective disul®de bridge formation was avoided. (The disul®de bonds omitted or replaced were assumed to contribute to the stabilization of the structure rather than being involved in enzyme±inhibitor interactions.) For this reason, one of the cysteine residues (Cys17 in MP1 and MP2, Z. Mucsi et al. and Cys19 in MP3) was replaced by glutamic acid and the gcarboxyl group of the latter was condensed with the N-terminal amino group of the tail peptide, to form an amide bond instead of the disul®de bridge.
Evaluation of the activity and structure of the model peptides In each model, the effectiveness of preserving the molecular structure by both the Gly±Gly`bridge' and the side-chain gpeptide bond was checked by short molecular dynamics (MD) runs using SYBYL (Tripos, 2001) . Initially, two models were chosen on the basis of comparisons of preliminary MD properties of the model peptides and SGCI. MP1 was constructed tentatively to behave as an inef®cient inhibitor model within a native-like SGCI scaffold. Owing to the drastic structural change, MP1 was thought to act as a possible substrate rather than a good inhibitor. As shown by preliminary MD calculations, the shortening of the molecule results in greater molecular mobility and also in exposing Phe10 to the surface of MP1. For that reason, the aromatic side chain of residue 10 was expected to be recognizable by chymotrypsin and hence the cleavage of the Phe10±Lys11 bond should lead to degradation of the inhibitor, regardless of the extent of enzyme±inhibitor±binding loop interaction. To avoid this effect associated with the native-like amino acid sequence, MP2 was constructed in which Phe10 is replaced by Thr. Furthermore, we presumed that a substrate may turn into an inhibitor if the conformation and the dynamic properties of the molecule are properly modi®ed. Thus MP3, incorporating more residues from the parent molecule SGCI than the two previous model peptides MP1 and MP2, was designed to behave as a medium-range inhibitor of chymotrypsin.
In order to test the above-mentioned hypothesis experimentally, the three selected model peptides were prepared and their inhibitory constants were determined by standard methods. The solution structure of all three model peptides was determined by homonuclear 1 H NMR spectroscopy. Molecular dynamics simulations (both in vacuum and in aqueous solution) were also performed both for SGCI and for MP1±3.
Materials and methods

Materials
Model peptides 1±3 (MP1±3) were prepared as described previously (Mucsi et al., 2002) . Sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS) was obtained from Cambridge Isotope Laboratories (Andover, MA), Bovine chymotrypsin, Nsuccinyl-Ala±Ala±Pro±Phe-p-nitroanilide, TRIS and Triton X-100 were purchased from Bachem (Bubendorf, Switzerland). Synthesis All three models were synthesized using convergent peptide synthesis (Riniker et al., 1993) as described earlier (Mucsi Fig. 3 . Structural basis of the design of model peptides MP1±3. Retained, discarded and modi®ed residues are indicated in relation to the parent molecule SGCI: bold, retained residues in all three models; underlined, residues retained only in MP3. Sequence numbering of the model peptides is consistent with that of SGCI. Retained parts comprise the C-terminal part (residues 29±35 in MP1 and MP2, 26±35 in MP3, referred to as`tail peptide'), containing the binding loop and the segment opposite to it,¯anked with several residues of strands b1 and b2 (residues 10±16 in MP1 and MP2, 8±18 in MP3), closed into a cyclopeptide with a Gly±Gly bridge. In MP1 and MP2, the Cys17±Cys28 disul®de was replaced with an isopeptide bond (gGlu17±Thr29), whereas in MP3 aǹ extra' linkage (gGlu19±Ala26) was introduced.
Design, structure and activity of inhibitor models et al., 2002). The tail peptides (Thr29±Gln35 or Ala26±Gln35 in SGCI) and the cyclopeptide part (residues 10±17 or 8±19 closed by a Gly±Gly bridge, according to the numbering of SGCI) of molecules ( Figure 3) were synthesized separately. Starting peptide fragments were prepared by the Fmoc (¯uorenyloxycarbonyl) technique in the solid phase (Atherton and Sheppard, 1989) . Cyclization was carried out with BOP [benzotriazol-1-yloxytris(dimethylamino)phosphonium hexauorophosphate] reagent (Atherton and Sheppard, 1989 ) in dilute DMF (N,N-dimethylformamide) solution containing NMM (N-methylmorpholine). Boc (tert-butoxycarbonyl) and t-Bu (tert-butoxy) protecting groups were cleaved by TFA (tri¯uoroacetic acid). The fragments were condensed in concentrated solution with BOP. The protecting groups were cleaved by HF containing anisole at ±5°C. The disul®de bridge was built up in MP1 and MP2 by iodine in HCl±acetic acid solution and in MP3 by oxygen in buffer solution (Andreu et al., 1994) . The purities of the peptide fragments and target molecules were checked by RP-HPLC. The ®nal products and the intermediates were puri®ed by HPLC and their structures were characterized by amino acid analysis and mass spectrometry. Enzyme inhibition Inhibitory activities were measured on a Shimadzu UV-210PC spectrophotometer (Shimadzu, Kyoto, Japan) at 410 nm using 3Q3 mm quartz cuvettes. The reaction mixture contained the following materials: 0.1 M NaCl, 0.05 M TRIS buffer (maintained at pH 8.0), 0.01 M CaCl 2 and 0.005% Triton X-100 as emulsi®er. As substrate, N-succinyl-Ala±Ala±Pro±Phe-p-nitroanilide (0.1 mM) was used. The selected model peptide was added in various concentrations ranging from 8.62 to 34.5 mM. The concentration of bovine chymotrypsin was set to 0.3 mM. The absorption curve recorded was analysed using the Progress data analysis program (Leatherbarrow, 1987) to determine the inhibitory constant K i using Equation 1 by a non-linear ®tting method (Dixon, 1972; Bieth, 1995) :
where [E 0 ] and [E] are the starting and actual concentrations, respectively, [I 0 ] is the initial concentration of the inhibitors or model peptides and K i * is the apparent value from which K i is calculated by the equation
where [S] is the concentration of the substrate and K m is its Michaelis±Menten constant. If necessary, the hydrolysis of the model peptides was monitored by using an ABI 471A amino acid sequencer. NMR spectroscopy The 1D and 2D homonuclear 1 H NMR spectra of all three model peptides (1.5 mg) dissolved in H 2 O±D 2 O (9:1 v/v) were recorded at 297 K on a Bruker DRX 500 spectrometer. In the direct dimension the number of acquired data points was typically 2048 with 512 increments. Spin lock of~60 ms and a mixing time of 150 ms were used for TOCSY and NOESY measurements, respectively. Data processing in the t 2 dimension was carried out by zero ®lling up to 4096 points and applying a Kaiser window function. In the indirect dimension, zero ®lling up to 1024 points was applied and a shifted sine-bell window function was used. Spectra were referenced to internal DSS. For spectrum analysis, the triad module of the software SYBYL (Tripos, 2001) , running on an SGI R12000 workstation, was used. Resonance assignment was carried out according to the common procedure described in the literature (Red®eld, 1993) .
Structure calculations
Structure calculations were based on NOE-derived distance restraints which were obtained from integration of the NOESY cross-peaks by using the module triad of the program SYBYL (Tripos, 2001) . Based on the relative size of the integrals, restraints were classi®ed into three categories corresponding to distance ranges of 1.8±2.5, 1.8±3.5 and 1.8±5.0 A Ê . The 1.8 A Ê value was chosen as a good approximation of the sum of the van der Waals radii of two geminal but non-overlapping hydrogen atoms (e.g. Ha 1 and Ha 2 of a Gly residue). Structure calculations were carried out with the program X-PLOR 3.851 by using standard simulated annealing protocols (Nilges et al., 1988 (Nilges et al., , 1991 . High-temperature calculations were run at 1000 K for 3000 steps followed by 3000 cooling steps with the NOE scale parameter set to 50. For each molecule a family of 100 structures were calculated. For comparison, 10 structures were accepted with good geometry parameters, in which no NOE violations >0.3 A Ê occurred. Molecular dynamics calculations MD calculations for synthetic model peptides MP1±3 and SGCI were carried out both in vacuum (Procedure A) and in explicit aqueous solution [Procedure B, similar to the approach described by Li and Daggett (Li and Daggett, 1995) ] using the program package GROMACS 3.0.2 (Lindahl et al., 2001 ) on a 450 MHz Pentium II PC running Linux. In both cases all Asp and Glu residues were considered as negatively charged and Lys and Arg side chains as protonated. For each synthetic model peptide and SGCI, the average NMR structure was chosen as the starting conformation. All minimizations were carried out with the steepest descent method. Procedure A. Models were ®rst minimized to the rather small 500 kJ mol ±1 nm ±1 force limit. MD simulation was run for 10 ns (5Q10 6 steps) at 300 K by using a time step of 2 fs. Structures were saved every 0.5 ps for further analysis. Procedure B. After having minimized to the 500 kJ mol ±1 nm ±1 force limit, the peptide (at neutral pH) was surrounded by water molecules. Simulations were run in a rectangular box, with walls at least 0.5 nm away from any of the peptide atoms. Energy minimizations were carried out ®rst with all water moieties and subsequently with all peptide atoms frozen, to the 500 kJ mol ±1 nm ±1 force limit. To ensure that the water molecules ®lled the simulation box smoothly, MD calculations were run only on the water molecules for 500 ps (2.5Q10 5 steps). Subsequently, water molecules were minimized once again; thereafter, the whole system was minimized. The full MD simulation with no constraints was run for 1 ns (5Q10 5 steps) with a 2 fs time step at 300 K. For analysis, structures were saved every 0.5 ps.
Results
Inhibition of chymotrypsin by the model peptides
Biological studies revealed that MP1 has no signi®cant inhibitory activity on chymotrypsin (K i = 2.24Q10 ±4 mol dm ±3 ; Table I ). Our results indicate that MP1 contains two cleavage sites for chymotrypsin: additionaly to the P1±P1¢ (Leu30±Lys31) site, the Phe10±Lys11 bond is also hydrolyzed. MP2 derived from MP1 by replacing Phe10 with Thr also does not inhibit chymotrypsin (K i = 3.70Q10 ±2 mol dm ±3 ; Table I ). For this molecule, no proteolytic cleavage other than that at the P1±P1¢ bond was observed. In MP3, the critical Phe10 was replaced by chymotrypsinresistant Ile10 because the latter residue is ready to form a bsheet motif and may also substitute Phe10 with respect to its hydrophobic core-forming ability. Consistent with our expectations, MP3 proved to be an effective inhibitor of bovine chymotrypsin (K i = 3.0Q10 ±7 mol dm ±3 ), although not completely comparable to the wild-type SGCI (Table I ). However, the K i value measured for MP3 is not only higher than the limit accepted for inhibitory activity but is almost equal to that obtained for SGTI, a natural inhibitor (K i = 2.1Q10 ±7 mol dm ±3 ) for trypsin. In the case of MP3, in which the P1±P1¢ sequence is conserved, the enhanced steric cooperativity, i.e. the decreased mobility and a more rigid binding loop, are able to convert a substrate into an inhibitor.
Because steric factors including 3D structure and conformational motions seem to be important in determining the substrate or inhibitory character, we investigated the solution structure and MD properties of MP1±3 by NMR spectroscopy and MD simulations.
Resonance assignment of the NMR spectra The assignment of chemical shifts was straightforward for all three molecules. All residues could be unambiguously identi®ed from the homonuclear spectra. Design, structure and activity of inhibitor models model peptides and those of SGCI can be compared directly (Figure 4) .
The Ha chemical shifts of MP1 and MP2 are very similar, indicating related conformations. In contrast, the chemical shift values of MP3 deviate from those of both MP1/MP2 and SGCI. The greatest difference in NH chemical shifts was observed for Glu19, Cys17 and Cys19, as these residues (and their chemical environment) were altered mostly in this model peptide. Large differences in DdNH and DdHa values were also found for Lys13 too, but the DdHa values for this residue are not signi®cant. The unusual values of dNH and dHa found for Lys13 in SGCI may be indicative of a structurally important, uncommon backbone conformation in the middle of the backside loop (Lys11±Asp15) located close to the protease binding loop. In contrast to Lys13, Lys31 exhibits the usual chemical shift values in SGCI and the DdNH and DdHa values of this residue obtained for SGCI and MP3 are small. This fact possibly re¯ects that in MP3 the structure of Lys31, the P1¢ residue in the binding loop, is close to its native conformation observed in SGCI. Solution structure of the model peptides The solution structure of each model peptide was determined by homonuclear 1 H NMR spectroscopy. MP1 has no wellde®ned structure ( Figure 5A ) owing to the small number of NOE-derived distance restraints which could be used in the structure calculations (Table II) . R.m.s.d. values of the 10 best structures of MP1 are shown in Table III . The binding loop also seems to be present in multiple conformations. As expected, the aromatic side chain of Phe10 is no longer buried in the molecule but exposed to solvent, which is in sharp contrast to what was found in native SGCI. The results obtained for MP2 are very similar to those for MP1. Similarly to MP1, we could not identify any traces of b-strands in MP2.
In contrast to MP1 and MP2, owing to the increased number of distance restraints (348), the structure of MP3 could be determined with acceptable accuracy. Its overall fold is reminiscent of that of SGCI ( Figure 5C ). The number of distance restraints (Table II) is suf®cient to obtain a relatively well-de®ned ensemble of a single conformer. Although most r.m.s.d. values (Table III) In MP3, the NOE cross-peaks observed between the Ha±Hb and Hb±Hb atoms of Cys residues allowed the identi®cation of the disul®de bridges (Klaus et al., 1993) , namely Cys17±Cys28 and Cys14±Cys33 (Mucsi et al., 2002) . According to the NMR spectroscopic investigations, the most rigid parts of this model are the 11±16 loop and the binding loop (28±33), and the most mobile sequence is the Gly±Gly part. Although there are no segments in the molecule that can be unambiguously classi®ed as b-sheets, the cyclopeptide adopts an elongated conformation indicative of interactions between segments Thr9±Lys11 and Thr16±Arg18, as con®rmed by circular dichroism (CD) 
Hb±Ha (2) Hd±NH (2) ± Thr16 NH±NH, Hb±NH, Hg±NH, Hb±Hg, NH±Hg
The ®rst atoms correspond to the residues in columns, the second atoms to the residues in rows. Numbers in brackets represent the number of NOEs if >1.
spectroscopy (Mucsi et al., 2002) . As expected from the design of the molecule, the Ile10 residue can form a weak hydrophobic core' but the structure around Ile10 differs signi®cantly from that around Phe10 in SGCI. The aromatic ring of Phe10 in SGCI gives NOE cross-peaks associated with Val2, Cys4, Thr8, Asp12, Cys17, Cys19 and Ala26, whereas Ile10 in MP3 gives NOE peaks only with Cys17. In this respect, however, it should be taken into account that the segments 1±6 and 21±25 are missing in MP3 and Cys19 was substituted by Glu.
The most notable structural feature of MP3 is that the orientation of the binding loop with respect to the other parts (11±16) of the molecule is the`mirror image' of the conformation observed in SGCI, i.e. the binding loop is in a similar conformation but on the opposite side of the region de®ned by residues 13±17. Although the number of distance restraints for this region is signi®cantly less than in the case of SGCI (Table IV) , the described orientation of the binding loop was consistently obtained in the course of structure calculations with X-PLOR. Taking into account that the binding loop is well de®ned (see above), we conclude that the interactions between this loop and the rest of the molecule are not fully native-like. This fact is especially intriguing considering that the molecule is an effective inhibitor.
Backbone torsion angles of binding loop residues in SGCI and the three model peptides are shown in Table V . It should be noted that there is no observable tendency in the values. In all three models the f and y values deviate from the thè canonical' ones (Laskowski and Qasim, 2000) , but this is also the case for the excellent inhibitor SGCI (Ga Âspa Âri et al., 2002) . The deviation of torsion angles is in good agreement with the backbone r.m.s.d. of this segment.
Molecular dynamics simulations of the model peptides
To estimate the internal mobility of the inhibitor models, we performed long-time (10 ns) MD simulations in vacuum and short-time (1 ns) runs in water for each of the model peptides and SGCI. The starting conformer for simulations was chosen to be the one closest to the average structure obtained from the NMR structure calculations. To avoid misinterpretation of the observed conformational changes, the ®rst 200 ps of the simulation time was excluded from the structural comparisons presented below.
The mobility of Ca atoms in the peptide backbone shows that MP1 and MP2 exhibit greater structural¯uctuations than MP3, which is still less rigid than SGCI. This is most pronounced for regions corresponding to the b-strands (residues 9±11, 16±19 and 26±29) of native SGCI. The¯uctuation of backbone torsion angles (f, y) in the binding loop of the peptides indicates greater conformational¯exibility in the case of MP1 and MP2 than for MP3 and the most constrained SGCI. Moreover, in SGCI and MP3, coordinated motion of the Torsion angles were calculated with MOLMOL (Koradi et al., 1996) . In the last row the torsion angles of`typical' canonical inhibitors are shown (Laskowski and Qasim, 2000) . Fig. 6 . Comparison of conformational changes of the binding loop and the segment opposite to it during the MD simulations in SGCI and MP3. The selected parameters presented are t`pseudo-torsional angles' (Ca i ±Ca i + 1 ± Ca i + 2 ±Ca i + 3 ) de®ned by the Ca atoms of residues 29±32 and 14±17. t values of the segments 29±32 (solid line) and 14±32 (dotted line) of (A) SGCI and (B) MP3. The simulation time shown ranges from 250 to 800 ps; the curves are smoothed (values are averages of the selected T20 neighbouring data points). To allow easier comparison, all t angles were adjusted to be 0 at 200 ps. The correlated motions of the two segments can be identi®ed, although a small delay in the conformational changes is apparent.
Design, structure and activity of inhibitor models binding loop and the segment opposite to it (residues 14±17) can be observed (Figure 6 ).
Discussion
Comparison of MP1 and MP2
On the basis of the inhibitory properties of MP1, it may be concluded that the peptide bond next to Phe10 is a suitable site for chymotrypsin, as speculated at the stage of peptide design. As structural data con®rm, in MP1 the side chain of this residue is exposed to solvent, as many of the side chains interacting with Phe10 in SGCI are missing from MP1. In MP2, Phe10 was replaced by Thr. Thr frequently takes part in a b-sheet motif (Prevelige and Fasman, 1989) and is more polar than Phe with a b-branching side chain not preferred by the substrate-binding cleft of chymotrypsin. The fact that MP1 has a smaller K i than MP2 may be due to the second cleavage site (Phe10±Lys11) in the cyclopeptide part. We assume that the K i values of the cleavages are independent and we are measuring the K i value of the stronger complex. Thus the value K i = 10 ±4 mol dm ±3 is associated with the tighter complex actually formed at the second site (Phe10±Lys11) rather than at the P1±P1¢ site (Leu30±Lys31). This suggestion is consistent with other data in the literature: the K i inhibitory constant is decreased by two orders of magnitude when the P1 Leu residue is changed to Phe in some canonical inhibitors (Ardelt and Laskowski, 1991; Laskowski and Qasim, 2000) . Additionally, substrates containing Phe at position P1 bind one or two orders of magnitude better to the enzyme than those with Leu in the same position (Antal et al., 2001) . While designing MP1 and MP2, based on preliminary structural studies, it was assumed that these two model peptides are too small to maintain the effective conformation and mobility of the binding loop. Our results obtained from MD simulations are in agreement with these expectations, as the relatively increased mobility of the backbone of the cyclopeptide (when compared with both MP3 and SGCI) is associated with different dynamics of the binding loop region. Structure and activity of MP3 MP3 was designed to be a more effective inhibitor than MP1 and MP2. Therefore, both its cyclopeptide scaffold and its tail peptide which contains the binding loop residue are larger than in the other two model peptides. Furthermore, MP3 also contains the Cys28±Cys19 disul®de bond replaced by an isopeptide bond in the former two models MP1 and MP2. The critical residue Phe10 is replaced by Ile because of its higher bsheet-forming potential compared with Thr (Prevelige and Fasman, 1989) . On the other hand, the apolar Ile10 residue was expected to substitute Phe10 suf®ciently well in organizing the interacting hydrophobic side chains.
Both the activity and the structural features of MP3 are closer to those of SGCI than MP1 and MP2. The well-de®ned structure of MP3 is comparable to that of SGCI, although there are still considerable differences. The lack of`genuine' bstrands and the different relative orientation of the binding loop with respect to the rest of the molecule should be mentioned. However, the chemically moi®ed scaffold of MP3 proved to be suitable for maintaining a biochemically ef®cient conformation of the protease binding loop. The importance of the proper scaffold is apparent when the ineffective peptides MP1 and MP2 are considered. The conformational and biochemical similarity of the model peptides to SGCI is interdependent, best exempli®ed by MP3, as its structural and dynamic properties appear to be suitable for inhibition. Conclusions The structure±activity relationships of the three model peptides of similar structure reveal the signi®cance of the structure and dynamics of the binding loop of protease inhibitors. The importance of the conformation and¯exibility of the protease binding loop has already been discussed in the literature (Laskowski and Qasim, 2000) and is continuously re®ned (Cai et al., 2002) . However, to the best of our knowledge, our study is the ®rst systematic investigation in the ®eld using the approach of structure-oriented dissection of an inhibitor and reconstruction of the relevant parts with chemical synthesis to yield model peptides. Our results suggest that the scaffold holding' the binding loop (especially residues 13±16) plays an essential role in maintaining the proper conformation and mobility of the residues located in the reactive site. The test system that we have developed allows the adjustment of the structural features of this scaffold, the tuning of the inhibitory activity and the evaluation of the changes introduced. We suggest that similar approaches can effectively contribute to the understanding of serine protease inhibition and, more generally, to protein±protein interactions and can also be useful in rational molecule design.
